Crossject Société Anonyme (EPA:ALCJ)

Market Cap	81.61M
Revenue (ttm)	4.12M
Net Income (ttm)	-12.80M
Shares Out	52.32M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	2.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	192,128
Average Volume	202,296
Open	1.566
Previous Close	1.560
Day's Range	1.560 - 1.630
52-Week Range	0.720 - 2.750
Beta	0.84
RSI	46.29
Earnings Date	Sep 18, 2025

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The c...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2001
• Employees: 102
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCJ

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.